HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (1- azabicyclo(2.2.2)oct- 3- yl)- 6- quinolinecarboxamide

structure in first source

Also Known As:

EVP-5141; N-(1-azabicyclo(2.2.2)oct-3-yl)-6-chinolinecarboxamide

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Bridged-Ring Heterocyclic Compounds
  - Quinuclidines: 20
    - N-(1-azabicyclo(2.2.2)oct-3-yl)-6-quinolinecarboxamide: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - N-(1-azabicyclo(2.2.2)oct-3-yl)-6-quinolinecarboxamide: 1

Experts

1.	Boess, Frank G: 1 article (05/2013)
2.	Erb, Christina: 1 article (05/2013)
3.	Flessner, Timo: 1 article (05/2013)
4.	Hendrix, Martin: 1 article (05/2013)
5.	König, Gerhard: 1 article (05/2013)
6.	Luithle, Joachim: 1 article (05/2013)
7.	Methfessel, Christoph: 1 article (05/2013)
8.	Schnizler, Katrin: 1 article (05/2013)
9.	Wiese, Welf-Burkhard: 1 article (05/2013)
10.	de Vry, Jean: 1 article (05/2013)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 05/01/2013 - "EVP-5141 improved performance in several learning and memory tests in both rats and mice, supporting the hypothesis that α7 nAChR agonists may provide a novel therapeutic strategy for the treatment of cognitive deficits in Alzheimer's disease or schizophrenia."
2.	Alzheimer Disease (Alzheimer's Disease) 05/01/2013 - "EVP-5141 improved performance in several learning and memory tests in both rats and mice, supporting the hypothesis that α7 nAChR agonists may provide a novel therapeutic strategy for the treatment of cognitive deficits in Alzheimer's disease or schizophrenia."